Andrew Hirsch, C4 Therapeutics CEO

C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

C4 Ther­a­peu­tics, one of the ear­ly play­ers in tar­get­ed pro­tein degra­da­tion, has linked up with Chi­na-based Bet­ta Phar­ma­ceu­ti­cals to de­vel­op C4’s non-small cell lung can­cer (NSCLC) treat­ment across the Pa­cif­ic.

On Tues­day, C4 an­nounced that it has inked an ex­clu­sive li­cens­ing agree­ment with Bet­ta to de­vel­op and com­mer­cial­ize its NSCLC treat­ment, CFT8919, in Greater Chi­na. The deal will see Bet­ta hand C4 $35 mil­lion, in­clud­ing a $10 mil­lion pay­ment up­front and a $25 mil­lion one-time eq­ui­ty pay­ment. This eq­ui­ty pay­ment will be com­plet­ed fol­low­ing the reg­u­la­to­ry ap­provals and clos­ing con­di­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA